Therapeutic Advances in Drug Safety

Papers
(The TQCC of Therapeutic Advances in Drug Safety is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews53
Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination27
Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance27
Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review25
The danger of diazoxide in the neonatal intensive care unit22
Pharmacovigilance: reporting requirements throughout a product’s lifecycle21
The patterns and implications of potentially suboptimal medicine regimens among older adults: a narrative review21
Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge20
The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and 19
Anticholinergic burden measures and older people’s falls risk: a systematic prognostic review19
Definition of self-medication: a scoping review16
Attitudes of ambulatory care older Nepalese patients towards deprescribing and predictors of their willingness to deprescribe15
Systematic review of immunosuppressant guidelines in the COVID-19 pandemic13
Impact of deprescribing dual-purpose medications on patient-related outcomes for older adults near end-of-life: a systematic review and meta-analysis13
Safety surveillance and challenges in accelerated COVID-19 vaccine development12
Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases12
Inappropriate medications and physical function: a systematic review11
Self-medication and the ‘infodemic’ during mandatory preventive isolation due to the COVID-19 pandemic10
Drug safety of frequently used drugs and substances for self-medication in COVID-1910
Patients’ attitudes toward deprescribing and their experiences communicating with clinicians and pharmacists10
Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database9
Patient harm from cardiovascular medications9
Prevalence and global trends of polypharmacy among people living with HIV: a systematic review and meta-analysis9
Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes9
Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies9
Analysis of the nature and contributory factors of medication safety incidents following hospital discharge using National Reporting and Learning System (NRLS) data from England and Wales: a multi-met8
Trends in potentially inappropriate opioid prescribing and associated risk factors among Korean noncancer patients prescribed non-injectable opioid analgesics8
Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials8
Renin–angiotensin–aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis8
The safety of ceftolozane-tazobactam for the treatment of acute bacterial infections: a systemic review and meta-analysis7
Ten-year trends in adverse drug reaction–related hospitalizations among people with dementia7
The use of a clinical decision support tool to assess the risk of QT drug–drug interactions in community pharmacies7
Anticholinergic burden in older adult inpatients: patterns from admission to discharge and associations with hospital outcomes7
Awareness, knowledge, and attitude toward adverse drug reaction (ADR) reporting among healthcare professionals in Ghana7
Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS7
Optimising medicines use in older adults with intellectual disability who have epilepsy: challenges and perspectives6
Effectiveness of drug postmarketing all-case surveillance as a safety measure in Japan6
0.026660919189453